photonamic GmbH and Co. KG was founded in 2002 with the objective of developing 5-aminolevulinic acid in the field of fluorescence diagnosis and photodynamic therapy.
photonamic’s research and development work for 5-aminolevulinic acid and other photosensitisers cover both therapeutic and diagnostic approaches in the areas of oncology, dermatology and other indications.
With Gliolan®, photonamic - in cooperation with medac GmbH - developed a drug for the intraoperative visualisation of malignant brain tumors (glioblastoma, WHO grade III-IV). Gliolan® was first approved in Europe in 2007 via a centralised procedure. Gliolan® is marketed in various countries throughout a network of partnerships.
In the field of dermatology, photonamic has developed Alacare®, a 5-aminolevulinic acid containing patch with integrated light protection for the photodynamic treatment of mild actinic keratoses. Alacare® was approved in Europe in 2009 via a decentralised procedure and since 2013 it is also distributed in Switzerland.
In the Netherlands, Belgium, Czech Republic, Slovakia and Australia, Alacare® is not only approved for mild but also for the treatment of moderate actinic keratosis.
As a development company, photonamic aims to license out its products to qualified partners for marketing and distribution.
In addition, photonamic co-operates closely with companies working in the field of fluorescence diagnosis and photodynamic therapy. This provides access to both light sources and light delivery systems and to new photosensitiser compounds.
photonamic GmbH & Co. KG